Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross‐sectional results of a German multicentre observational study (PROSa)
| Autor: | Daniel Pink, Armin Tuchscherer, Diana I Dmytrow, Martin Eichler, Jens Jakob, Franka Menge, Stephan Richter, Peter Hohenberger, Leopold Hentschel, Markus K. Schuler, Johannes Mohm, Jochen Schmitt, Robert Grützmann, Annegret Kunitz, Karin Arndt, Bernd Kasper, Martin Bornhäuser, Susanne Singer, Dimosthenis Andreou, Marit Ahrens, Peter Reichardt |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Gastrointestinal Stromal Tumors medicine.drug_class Group comparison Tyrosine-kinase inhibitor Quality of life Surveys and Questionnaires Bayesian multivariate linear regression Internal medicine Humans Medicine ddc:610 Protein Kinase Inhibitors GiST business.industry Cancer Gastrointestinal stromal tumours medicine.disease humanities Cross-Sectional Studies Quality of Life Observational study business |
| Zdroj: | European Journal of Cancer Care. 30 |
| ISSN: | 1365-2354 0961-5423 |
| DOI: | 10.1111/ecc.13484 |
| Popis: | Objective We investigated the health-related quality of life (HRQoL) of patients with gastrointestinal stromal tumours (GIST). Methods In the multicentre PROSa study, the HRQoL of adult GIST patients was assessed between 2017 and 2019 using the European Organisation for Research and Treatment of Cancer HRQoL questionnaire (EORTC QLQ-C30). We performed group comparisons and multivariate linear regressions. Results Among 130 patients from 13 centres, the mean global HRQoL was 63.3 out of 100 points. Higher sores indicate better HRQoL. The highest restrictions were in emotional, social, role functioning, insomnia, fatigue, and pain. In multivariate linear regression, we found no significant differences between patients receiving tyrosine kinase inhibitor (TKI) treatment and those without TKI treatment as well as between patients treated with curative or with palliative intent. Patients who received multiple lines of TKI treatment had the most restrictions, notably in physical (unstandardized regression coefficient [B] = -15.7), role (B = -25.7), social (B = -18.4), and cognitive functioning (B = -19.7); fatigue (B = 15.93); general health (B = -14.23); and EORTC-sum score (B = -13.82) compared to all other patients. Conclusion The highest HRQoL restrictions were in GIST patients receiving multiple lines of TKI therapy. Underlying causes need further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|